An Open-label Phase Ib/II, Multi-center Study of 4SC-202 in Combination With Pembrolizumab in Patients With Unresectable Stage III/Metastatic Stage IV Cutaneous Melanoma Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy

Trial Profile

An Open-label Phase Ib/II, Multi-center Study of 4SC-202 in Combination With Pembrolizumab in Patients With Unresectable Stage III/Metastatic Stage IV Cutaneous Melanoma Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Mar 2018

At a glance

  • Drugs 4SC 202 (Primary) ; Pembrolizumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Acronyms SENSITIZE
  • Sponsors 4SC
  • Most Recent Events

    • 21 Mar 2018 According to a 4SC media release, this study is expected to complete in H1 2019.
    • 06 Nov 2017 According to a 4SC media release, the first patient has been enrolled in this trial. Prof. Dirk Schadendorf is the principal investigator of this trial. Top-line results from this trial are expected in H2 2018.
    • 26 Oct 2017 According to a 4SC media release, After opening the first clinical center in Q3 2017, company is anticipating to enroll the first patient in Q4 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top